Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Mar;28(3):308-13.
doi: 10.1177/0883073812446485. Epub 2012 Jun 29.

Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures

Affiliations
Comparative Study

Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures

Mi-Sun Yum et al. J Child Neurol. 2013 Mar.

Abstract

Tuberous sclerosis complex is a genetic disorder resulting in epilepsy and mental retardation. Vigabatrin has shown efficacy in the treatment of infantile spasms caused by tuberous sclerosis complex, but its effects on focal seizures caused by tuberous sclerosis complex have not been determined. We compared the efficacy of vigabatrin in patients with tuberous sclerosis complex-induced focal seizures and infantile spasms and assessed the mental outcomes in both groups. We retrospectively evaluated 31 children with tuberous sclerosis complex and epilepsy, who were treated with vigabatrin in a single tertiary center in Seoul, Korea. Vigabatrin treatment resulted in spasms cessation in 16 of 18 (88.9%) patients with infantile spasms, whereas 6 of 13 (46.2%) patients with focal seizures became seizure free. Initial response to vigabatrin had no effect on intellectual disability. Vigabatrin was highly effective in eliminating infantile spasms caused by tuberous sclerosis complex but was less effective in patients with focal seizures.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

None of the authors has any conflict of interest to disclose.

Figures

Figure 1
Figure 1
Study design. Of the 39 patients with tuberous sclerosis complex and epilepsy, 31 patients had been treated with vigabatrin as first- or second-line therapy within 1 month of seizure onset. Patients were divided into those with infantile spasms and focal seizures at initiation of vigabatrin, except for one patient with concurrent infantile spasms and focal seizures, who was regarded as having infantile spasms. Thus, 18 patients had infantile spasms (underlined) and 13 had focal seizures (italics). Of the 17 patients who initially presented with infantile spasms, 9 evolved to other types of epilepsy, whereas, of the 13 patients who initially presented with focal seizures, only one evolved to infantile spasms. Abbreviations: TSC, tuberous sclerosis complex; VGB, vigabatrin; IS, infantile spasms; focal seizures, focal seizures; LGS, Lennox-Gastaut syndrome; ACTH, adrenocorticotropic hormone; VPA, valproic acid

Similar articles

Cited by

References

    1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345–1356. - PubMed
    1. Thiele EA. Managing and understanding epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51 (Suppl 1):90–91. - PubMed
    1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657–668. - PubMed
    1. Jambaque I, Chiron C, Dumas C, et al. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res. 2000;38:151–160. - PubMed
    1. Angehagen M, Ben-Menachem E, Ronnback L, et al. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res. 2003;28:333–340. - PubMed

Publication types